ArticleBMC cancer2022

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).

Tomoya Fukui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.